A Swiss-based biotech founded out of a university engaged with DIAMANTE via their seed investor. DIAMANTE provided fractional management support to the company to lead their small molecule oncology program from lead identification/optimization to successful clinical candidate selection.
Specifically, this involved leadership of a virtual drug development team consisting of university personnel, CROs, and consultants. To guide the drug discovery efforts a screening funnel and TPP were established to allow a targeted selection of best compounds with all critical development properties (i.e. potency, efficacy, selectivity, ADME / physical & chemical properties, PK, tox profile, chemistry, and IP).
In parallel, DIAMANTE coordinated the preparation of the preclinical and clinical development plan for Series A engaging with CROs, Clinical experts and providing drug development expertise.